Results of the ORAL Surveillance study showed a higher risk for major adverse CV events and venous thromboembolism with tofacitinib vs TNFis.
The data were compared with the 2018 ACG and 2020 AGA guidelines for UC and the 2019 ACG and 2021 AGA guidelines for CD.
By identifying existing medications that may be repurposed for dementia, clinicians may be able to provide faster treatment for those in need.
Researchers compared the effectiveness of tofacitinib and vedolizumab among patients with UC who had experienced anti-TNF failure.
Tofacitinib 5mg, 10mg; tabs.
Tofacitinib 11mg, 22mg; ext-rel tabs.
Tofacitinib 1mg/mL; grape flavor; contains sucralose, xylitol.